Unknown

Dataset Information

0

Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.


ABSTRACT: Sustained antiviral responses of chronic hepatitis C virus (HCV) infection have improved recently by the use of direct-acting antiviral agents along with interferon (IFN)-? and ribavirin. However, the emergence of drug-resistant variants is expected to be a major problem. We describe here a novel combinatorial small interfering RNA (siRNA) nanosome-based antiviral approach to clear HCV infection. Multiple siRNAs targeted to the highly conserved 5'-untranslated region (UTR) of the HCV genome were synthesized and encapsulated into lipid nanoparticles called nanosomes. We show that siRNA can be repeatedly delivered to 100% of cells in culture using nanosomes without toxicity. Six siRNAs dramatically reduced HCV replication in both the replicon and infectious cell culture model. Repeated treatments with two siRNAs were better than a single siRNA treatment in minimizing the development of an escape mutant, resulting in rapid inhibition of viral replication. Systemic administration of combinatorial siRNA-nanosomes is well tolerated in BALB/c mice without liver injury or histological toxicity. As a proof-of-principle, we showed that systemic injections of siRNA nanosomes significantly reduced HCV replication in a liver tumor-xenotransplant mouse model of HCV. Our results indicate that systemic delivery of combinatorial siRNA nanosomes can be used to minimize the development of escape mutants and inhibition of HCV infection.

SUBMITTER: Chandra PK 

PROVIDER: S-EPMC3437587 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.

Chandra Partha K PK   Kundu Anup K AK   Hazari Sidhartha S   Chandra Sruti S   Bao Lili L   Ooms Tara T   Morris Gilbert F GF   Wu Tong T   Mandal Tarun K TK   Dash Srikanta S  

Molecular therapy : the journal of the American Society of Gene Therapy 20120522 9


Sustained antiviral responses of chronic hepatitis C virus (HCV) infection have improved recently by the use of direct-acting antiviral agents along with interferon (IFN)-α and ribavirin. However, the emergence of drug-resistant variants is expected to be a major problem. We describe here a novel combinatorial small interfering RNA (siRNA) nanosome-based antiviral approach to clear HCV infection. Multiple siRNAs targeted to the highly conserved 5'-untranslated region (UTR) of the HCV genome were  ...[more]

Similar Datasets

| S-EPMC1319196 | biostudies-literature
| S-EPMC7855861 | biostudies-literature
| S-EPMC5427965 | biostudies-literature
| S-EPMC7127796 | biostudies-literature
| S-EPMC2673075 | biostudies-literature
| S-EPMC6388173 | biostudies-literature
| S-EPMC4589515 | biostudies-literature
| S-EPMC7087333 | biostudies-literature
| S-EPMC9415367 | biostudies-literature
| S-EPMC4502978 | biostudies-literature